Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) expression, exhibits high invasiveness, metastatic potential, and poor prognosis. Current chemotherapy for metastatic TNBC is associated with low response rates and short progression-free survival. It is imperative to find new therapies for this […]
Read More